Grants and Contributions:
Title:
Feasibility - Development of mutanoma vaccines
Agreement Number:
1008613
Agreement Value:
$162,000.00
Agreement Date:
Aug 14, 2023 - Dec 31, 2024
Description:
Development of a curative cancer vaccine platform to elicit a personalized immune response against cancer cells
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Quebec, Quebec, CA G1R 1R2
Reference Number:
172-2023-2024-Q2-1008613
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
778574087
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 61 days.
Amendment Date
Dec 7, 2023
Recipient's Legal Name:
Angany inc.
Federal Riding Name:
Québec
Federal Riding Number:
24059
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
325410
Amendments: